Login / Signup

Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.

Lucas LiaudetCsaba Szabo
Published in: Critical care (London, England) (2020)
Keyphrases
  • coronavirus disease
  • sars cov
  • early onset
  • respiratory syndrome coronavirus
  • binding protein
  • drug induced